恩替卡韦与阿德福韦酯对HBeAg阳性乙肝肝硬化失代偿期患者肝功能的影响

2017-05-18 16:36:46王运才
中外医疗 2017年8期
关键词:恩替卡韦临床疗效

王运才

[摘要] 目的 对比恩替卡韦与阿德福韦酯对HBeAg阳性乙肝肝硬化患者肝功能的影响。方法 方便选取2015年1月—2016年6月该院收治的HBeAg阳性失代偿期乙肝肝硬化患者85例作为研究对象,根据治疗方案的差异将其分为恩替卡韦组与阿德福韦酯组,两组患者治疗前人口学特征、肝功能状况、病毒学资料比较差异无统计学意义,其中阿德福韦酯组40例患者应用阿德福韦酯治疗,恩替卡韦组45例患者应用恩替卡韦治疗,比较两组患者治疗效果及治疗后肝功能变化情况。结果 两组患者治疗后ALT复常率及HBeAg转阴率比较(10.00%vs13.33%,72.50%vs71.11%),差异无统计学意义(P>0.05),治疗后恩替卡韦组TBIL、Child-Pugh评分、HBV DNA阴转率明显优于阿德福韦酯组,差异有统计学意义(P<0.05),两组患者治疗期间未见明显药物不良反应及肾功能变化。结论 恩替卡韦与阿德福韦酯治疗乙型病毒性肝炎失代偿性肝硬化均具有良好的疗效,但恩替卡韦对患者肝功能的改善效果更为显著,临床可结合患者实际病情选择恰当的药物治疗方案以提升临床治疗效果。

[关键词]恩替卡韦;阿德福韦酯;HBeAg阳性; 乙肝肝硬化;失代偿期;临床疗效

[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742(2017)03(b)-0043-03

[Abstract] Objective To compare the effect of entecavir and adefovir dipivoxil on the liver function of patients with HBeAg positive cirrhosis after hepatitis B. Methods 85 cases of patients with HBeAg positive cirrhosis after hepatitis B admitted and treated in our hospital from January 2015 to June 2016 were selected and divided into two groups according to the different treatment plans, and there were no obvious differences in the demographic characteristics, liver function condition and virus data, and the adefovir dipivoxil (40 cases) were treated with adefovir dipivoxil, while the entecavir group (45 cases) were treated with entecavir, and the treatment effect and changes of liver function after treatment were compared between the two groups. Results After treatment, the differences in the ALT recovery rate and HBeAg seroconversion rate between the two groups had no statistical significance(10.00% vs 13.33%,72.50% vs 71.11%)(P>0.05), after treatment, the TBIL, Child-Pugh score and HBV DNA seroconversion rate in the entecavir group were obviously better than those in the adefovir dipivoxil group(P<0.05), and there were no obvious drug adverse reactions and renal function changes during the treatment period. Conclusion Both entecavir and adefovir dipivoxil in treatment of cirrhosis after hepatitis B have a better curative effect, but the improvement effect of entecavir on the liver function is obvious, and we can select the proper drug treatment plan according to the practical condition of patients in order to improve the clinical treatment effect.

[Key words] Entecavir; Adefovir dipivoxil; HBeAg positive; Hepatitis B cirrhosis; Decompensated period; Clinical curative effect

近年來我国乙肝疫情整体得到初步控制,但乙肝仍为我国发病率最高的传染病之一。有临床调查显示,乙肝患者5年内并发肝硬化风险高达10.1%~17.3%,并且对于发生失代偿性的乙肝肝硬化患者其5年生存率更是低于30%[1-2],由于我国肝脏移植资源的短缺以及高昂的手术费用,绝大部分乙肝并发失代偿性肝硬化患者仅能依赖于抗病毒治疗维持生存,因此有效、安全、可靠的抗病毒药物治疗方案直接影响患者的生活质量及生存率[3]。该研究通过对比临床两种乙肝抗病毒药物恩替卡韦与阿德福韦酯,通过对2015年1月—2016年6月该院收治的85例HBeAg阳性失代偿期乙肝肝硬化进行对照研究,探讨其在乙肝失代偿性肝硬化临床治疗中的应用效果及对患者肝功能的影响,现报道如下。 ……

登录APP查看全文

猜你喜欢
恩替卡韦临床疗效
恩替卡韦治疗失代偿期乙肝肝硬化临床疗效分析
安络化纤丸对乙肝肝硬化的疗效评价
注射用核糖核酸联合恩替卡韦治疗乙肝肝硬化30例
拉米夫定联合阿德福韦酯与单用恩替卡韦治疗乙型肝炎肝硬化失代偿期的疗效观察
探讨氯吡格雷预防冠心病介入治疗心血管的临床疗效
131碘治疗甲亢患者的后期随访效果分析
枸橼酸咖啡因治疗早产儿原发性呼吸暂停临床分析
微创手术治疗胃溃疡42例临床分析
研究腹腔镜在早期卵巢癌分期手术中的临床应用
早期应用前列地尔治疗急性脑梗死临床疗效观察